AB&B BIO-TECH-B (02627.HK): Adsorbed Tetanus Vaccine Wins CDE IND Clearance

NewTimeSpace News: On 13 November 2026, Jiangsu Ab&B Bio-Tech Co., Ltd. (stock code: 2627) published a voluntary announcement that the Center for Drug Evaluation of China's National Medical Products Administration approved the investigational new drug application for the Group's self-developed adsorbed tetanus toxoid vaccine candidate on 12 November 2026.

Tetanus is an acute specific infection caused when spores of Clostridium tetani enter the body through wounds and can be life-threatening. Prevention relies mainly on wound management and immunisation, with primary prevention through active immunisation using vaccines containing tetanus toxoid to build long-term immunity. The Group's candidate is designed to induce protective antitoxin antibodies through vaccination.

The approval marks important progress in the Group's research in traditional vaccines and lays the foundation for clinical studies of the candidate. The Group is a China-based vaccine company whose products include quadrivalent and trivalent influenza subunit vaccines and an investigational freeze-dried human rabies vaccine.

The Company also noted that trading in its H shares has been suspended since 9:00 am on 1 April 2026 and will remain suspended until further notice.